As coronavirus spreads, a biotech IPO squeaks through. Others may 'wait and see'

Can the sector’s long-running IPO momentum survive the unique challenge posed by the virus’s outbreak?

As coronavirus spreads, a biotech IPO squeaks through. Others may 'wait and see'
Can the sector’s long-running IPO momentum survive the unique challenge posed by the virus’s outbreak?